BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 31999199)

  • 21. Budget Impact Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) for Preventing Recurrent Clostridioides difficile Infection in the US.
    Lodise T; Guo A; Yang M; Cook EE; Song W; Yang D; Wang Q; Zhao A; Bochan M
    Adv Ther; 2023 Jun; 40(6):2801-2819. PubMed ID: 37093360
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An Observational Cohort Study of
    Rao K; Higgins PDR; Young VB
    mSphere; 2018; 3(3):. PubMed ID: 29794054
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A systematic review of real-world healthcare resource use and costs of
    Malone DC; Armstrong EP; Gratie D; Pham SV; Amin A
    Antimicrob Steward Healthc Epidemiol; 2023; 3(1):e17. PubMed ID: 36714290
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incidence of and risk factors for recurrent Clostridioidesdifficile infection in Japan using a claims database: A retrospective cohort study.
    Mikamo H; Kondo T; Okuyama K; Marcella SW; Ruzicka DJ
    Anaerobe; 2020 Feb; 61():102139. PubMed ID: 31830597
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Retrospective database analysis of healthcare resource utilization and costs in patients who develop post-transplant lymphoproliferative disease within the first year following allogeneic hematopoietic stem cell transplants.
    Watson C; Xu H; Princic N; Sruti I; Barlev A
    J Med Econ; 2020 Oct; 23(10):1159-1167. PubMed ID: 32643493
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk factors for recurrent Clostridium difficile infection (CDI) hospitalization among hospitalized patients with an initial CDI episode: a retrospective cohort study.
    Zilberberg MD; Reske K; Olsen M; Yan Y; Dubberke ER
    BMC Infect Dis; 2014 Jun; 14():306. PubMed ID: 24898123
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Estimating excess mortality and economic burden of Clostridioides difficile infections and recurrences during 2015-2019: The RECUR England study.
    Ghosh S; Antunes A; Rinta-Kokko H; Chaparova E; Lay-Flurrie S; Tricotel A; Andersson FL
    Int J Infect Dis; 2024 May; 142():106967. PubMed ID: 38368927
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Healthcare resource use and direct costs in severe aplastic anemia (SAA) patients before and after treatment with eltrombopag.
    Cai B; Said Q; Li X; Li FY; Arcona S
    J Med Econ; 2020 Mar; 23(3):243-251. PubMed ID: 31686551
    [No Abstract]   [Full Text] [Related]  

  • 29. Changes in healthcare resource use and costs associated with early versus delayed initiation of atypical antipsychotic adjunctive treatment in major depressive disorder.
    Seetasith A; Greene M; Hartry A; Burudpakdee C
    J Med Econ; 2018 Sep; 21(9):888-901. PubMed ID: 29862860
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral Vancomycin Prophylaxis as Secondary Prevention Against Clostridioides difficile Infection in the Hematopoietic Stem Cell Transplantation and Hematologic Malignancy Population.
    Morrisette T; Van Matre AG; Miller MA; Mueller SW; Bajrovic V; Abidi MZ; Benamu E; Kaiser JN; Barber GR; Chase S; Tobin J; Fish DN; Gutman JA
    Biol Blood Marrow Transplant; 2019 Oct; 25(10):2091-2097. PubMed ID: 31255741
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Economic and Clinical Burden of Acute Myeloid Leukemia Episodes of Care in the United States: A Retrospective Analysis of a Commercial Payer Database.
    Pandya BJ; Chen CC; Medeiros BC; McGuiness CB; Wilson SD; Walsh EH; Wade RL
    J Manag Care Spec Pharm; 2020 Jul; 26(7):849-859. PubMed ID: 32281456
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk factors for recurrent Clostridium difficile infection in hematopoietic stem cell transplant recipients.
    Huang AM; Marini BL; Frame D; Aronoff DM; Nagel JL
    Transpl Infect Dis; 2014 Oct; 16(5):744-50. PubMed ID: 25040545
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevention of recurrent Clostridioides difficile infection: A systematic review of randomized controlled trials.
    Madoff SE; Urquiaga M; Alonso CD; Kelly CP
    Anaerobe; 2020 Feb; 61():102098. PubMed ID: 31493500
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Burden of Crohn's disease in the United States: long-term healthcare and work-loss related costs.
    Manceur AM; Ding Z; Muser E; Obando C; Voelker J; Pilon D; Kinkead F; Lafeuille MH; Lefebvre P
    J Med Econ; 2020 Oct; 23(10):1092-1101. PubMed ID: 32609019
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Healthcare resource utilization and costs in the 12 months following hospitalization for respiratory syncytial virus or unspecified bronchiolitis among infants.
    Ledbetter J; Brannman L; Wade SW; Gonzales T; Kong AM
    J Med Econ; 2020 Feb; 23(2):139-147. PubMed ID: 31432723
    [No Abstract]   [Full Text] [Related]  

  • 36. Hospital cost of Clostridium difficile infection including the contribution of recurrences in French acute-care hospitals.
    Le Monnier A; Duburcq A; Zahar JR; Corvec S; Guillard T; Cattoir V; Woerther PL; Fihman V; Lalande V; Jacquier H; Mizrahi A; Farfour E; Morand P; Marcadé G; Coulomb S; Torreton E; Fagnani F; Barbut F;
    J Hosp Infect; 2015 Oct; 91(2):117-22. PubMed ID: 26253518
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Utilization of Health Services Among Adults With Recurrent Clostridium difficile Infection: A 12-Year Population-Based Study.
    Kuntz JL; Baker JM; Kipnis P; Li SX; Liu V; Xie Y; Marcella S; Escobar GJ
    Infect Control Hosp Epidemiol; 2017 Jan; 38(1):45-52. PubMed ID: 27760583
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Economic burden of spinal muscular atrophy in the United States: a contemporary assessment.
    Droege M; Sproule D; Arjunji R; Gauthier-Loiselle M; Cloutier M; Dabbous O
    J Med Econ; 2020 Jan; 23(1):70-79. PubMed ID: 31322019
    [No Abstract]   [Full Text] [Related]  

  • 39. Economic burden of primary compared with recurrent Clostridium difficile infection in hospitalized patients: a prospective cohort study.
    Shah DN; Aitken SL; Barragan LF; Bozorgui S; Goddu S; Navarro ME; Xie Y; DuPont HL; Garey KW
    J Hosp Infect; 2016 Jul; 93(3):286-9. PubMed ID: 27209056
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemotherapy-induced febrile neutropenia (FN): healthcare resource utilization (HCRU) and costs in commercially insured patients in the US.
    Flanigan JA; Yasuda M; Chen CC; Li EC
    Support Care Cancer; 2024 May; 32(6):373. PubMed ID: 38777864
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.